New vaccine against dengue arrives in Brazil next week

Protection

Immunizer was approved by Anvisa in March

The Brazilian Association of Vaccine Clinics (ABCVAC) reported that a new vaccine against dengue should arrive in Brazil next week. Composed of four different serotypes of the virus that causes the disease, Qdenga, from the company Takeda Pharma Ltda., was approved by the National Health Surveillance Agency (Anvisa) in March. According to the regulatory body, the dose provides broad protection against dengue.

In a note, ABCVAC reported that the price of the vaccine, initially available only in private laboratories, should vary between R$ 350 and R$ 500 for the final consumer, depending on the state. In São Paulo, for example, the Maximum Consumer Price (PMC) authorized by Anvisa for clinics is R$ 379.40.

“Clinics must use this parameter in the composition of their final pricing, which also includes care, screening, analysis of the vaccination booklet, pre- and post-vaccination guidance, in addition to all the support that patients need to inform themselves correctly about the issue of vaccination”, highlighted the ABCVAC.

Recommendation

According to Anvisa, the vaccine is indicated for children over 4 years of age, adolescents and adults up to 60 years of age. Qdenga, therefore, is the first dose approved in Brazil for a wider audience, since the vaccine previously approved, Dengvaxia, can only be used by those who have already had dengue.

The new vaccine will be available for subcutaneous administration in a two-dose scheme, with an interval of three months between applications.

“The granting of registration by Anvisa allows the sale of the product in the country, provided that the approved conditions are maintained. The vaccine, however, remains subject to the monitoring of adverse events, through pharmacovigilance actions under the responsibility of the company”, he informed.

Efficacy against dengue for all serotypes combined among seronegative individuals (with no prior virus infection) was 66.2%. For seropositive individuals (who had a previous infection with the virus), the rate was 76.1%.

“The demonstration of the efficacy of Qdenga is mainly supported by the results of a large-scale, phase 3, randomized, placebo-controlled study, conducted in endemic countries for dengue, with the objective of evaluating the efficacy, safety and immunogenicity of the vaccine. ”, reported Anvisa.

read more

Bolsonaro apologizes after fake news about graphene vaccines

In Amazonas, 69% of the municipalities have low and medium risk for dengue

Health launches campaign after increase in dengue, Zika and chikungunya